FDA-approved vs unapproved GLP-1 products: what patients should know

FDA-approved means reviewed for a specific product and use

An FDA-approved drug has been reviewed by FDA for safety, effectiveness, quality, labeling, and manufacturing for its approved use. That does not mean every product advertised online with a similar ingredient has the same status.

Unapproved products can create real risk

FDA has warned about unapproved GLP-1 products used for weight loss, including concerns about dosing errors, counterfeit drugs, fraudulent compounded products, and active pharmaceutical ingredients from unverified sources.

• Counterfeit products may contain too little, too much, or none of the active ingredient.
• Some products may use ingredients or forms that are not the approved product.
• Online sellers may blur the difference between FDA-approved medications, compounded products, and lookalike products.

The supply chain matters

FDA created a Green List import alert to help stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain. FDA has also said semaglutide and tirzepatide do not currently appear on the 503B bulks list or FDA's drug shortage list. That is a signal to ask direct sourcing and legal-basis questions when a provider advertises compounded or lookalike products.

The 503B bulk-substance proposal is still proposed

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list on April 30, 2026, saying it had not identified a clinical need for outsourcing facilities to compound those drugs from bulk substances. The Federal Register later extended the comment deadline to July 30, 2026, so this is still a proposed FDA action rather than a final determination. Patients do not need to follow docket mechanics, but they should avoid providers that describe the policy as settled in a way that hides uncertainty.

• Ask whether the product would come from a state-licensed pharmacy, an outsourcing facility, or another source.
• Ask what current lawful basis the provider believes applies if the product is compounded.
• Ask how the provider will notify patients if FDA or state rules change.

Match the label to a real pharmacy

FDA's June 2026 update says some fraudulent compounded semaglutide and tirzepatide products have been labeled as if they came from pharmacies that did not make them or as if they used incorrect pharmacy names. That turns pharmacy verification into a practical safety step, not paperwork.

• Ask for the dispensing pharmacy's legal name before payment.
• Check that the label, receipt, prescriber, and pharmacy contact information match what the provider told you.
• Call the pharmacy or clinician before using a product if labeling, packaging, or sourcing is unclear.

Questions before you pay

Ask the provider to name the exact product, active ingredient, pharmacy, source, dose form, and whether it is FDA-approved for the discussed use. If the answer is vague, do not rush.

A directory should not hide this distinction

GLP Clinic Finder should clearly separate FDA-approved products, compounded products, and unknown sourcing in future provider profiles so users can compare transparently.